文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 医药卫生 > 临床医学 > Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than
侵权投诉

Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than

Anti-VEGFtherapyforneovascularoculardiseasesCiullaandRosenfeld167

Table1Characterizationofneovascularoculardiseasesotherthanage-relatedmaculardegenerationOculardiseasePDR

NeovascularcharacteristicsRetinaoririsneovascularization;activeCNVleakage[12 ];DME[1 ];NVG[13–15]CentralRVO,hemicentralRVO,orbranchRVOwithischemicornonischemicobstructionbythrombosisorexternalcompression[18];

neovascularization[19];macularedema[20–22];NVG[13]

CNV;retinaldetachment

AffectedpopulationLeadingcauseofblindnessamongUSworkingpopulation

(20–74yearsold)Allages;however,51% rstdiagnosedat65yearsorolder[23]

AssociatedriskfactorsChronichyperglycemia[16]

Prevalence

4.1millioninUSA;900000inUSAwithvision-threateningdisease[17]

1.6%incidenceinUSpopulationover50yearsold[3,24]

RVO

Age;highbloodpressure;atheroscleroticdiseaseinretinalveins[24]

ROP

PathologicmyopiaCNV

AngioidstreaksCNV

PresumedocularhistoplasmosissyndromeRegressedCNVmembranes; brovasculardisciformscar[29]

IdiopathicpolypoidalCNV;detachmentofsensorychoroidalretinainthemacula[30,31]vasculopathyNVG

Angleclosuresecondarytoa brovascularmembraneinanteriorchamberduetoretinalischemiaandangiogenesis;ischemiccentralRVOin

58–86%ofaffectedeyes[33]

Lowgestationalage;lowbirthweight;useofsupplementaloxygentherapy;white[25]

Signi cantcauseofabnormalLacquercracksintheneovascularizationandvisionstretchingretinalossinyoungerUSpopulation(woundrepair)[27](under50yearsold)

Signi cantcauseofabnormalCrackeddisruptionsofneovascularizationandvisiontheelasticlayeroflossinyoungerUSpopulationBruch’smembrane(under50yearsold)(woundrepair)[17,28]Signi cantcauseofabnormalInfectionwithHistoplasmaneovascularizationandvisioncapsulatumlossinyoungerUSpopulation(under50yearsold)

Signi cantcauseofabnormalPigmentedrace;intraocularneovascularizationandvisionin ammation[32]lossinyoungerUSpopulation(under50yearsold)

Over40yearsold;maydevelopDiabetesevenwithoutin33–64%ofeyeswithPDR;impairedrenaluntreatedPDRfunction;

hypoalbuminemia[34]

Infants(lifelongeffects);

leadingcauseofblindnessinprematureneonates50–65%ofinfantsweighing 1250g[25,26]NA

NA

NA

NA

NA

CNV,choroidalneovascularization;DME,diabeticmacularedema;NA,notavailable;NVG,neovascularglaucoma;PDR,proliferativediabeticretinopathy;RAP,retinalangiomatousproliferation;ROP,retinopathyofprematurity;RPE,retinalpigmentepithelium;RVO,retinalveinocclusion.

Diabeticretinopathyanddiabeticmacularedema

Ocularmicrovascularcomplicationsaffectalmostallpatientswithtype1diabetesandatleast60%ofpatientswithtype2diabetes[35].Increasedpatientlongevity,alongwithincreasedobesity,hasledtoanincreasedprevalenceoftype2diabetes-associateddiabeticretino-pathy,whichistheleadingcauseofblindnessinthe

workingpopulation(age20–74years)indevelopedcountries[2].Visuallossmayoccurfromneovasculariza-tion,asinPDR,orfromincreasedretinalvascularper-meabilityleadingtodiffuseleakagefromcapillarywalls,focalleakagefrommicroaneurysms,andaccumulationof uidandmacromoleculesintheretina,asinDME[2,36,37].Theseconditionsarecharacterizedbyreduced

Table2Anti-vascularendothelialgrowthfactoragentscurrentlyavailableorindevelopmentforthetreatmentofneurovasculareyediseasesotherthanage-relatedmaculardegenerationAgent

Pegaptanib(Macugen)Ranibizumab(Lucentis)Bevacizumab(Avastin)VEGFtrap

Triamcinoloneacetonide(Kenalog-40)Bevasiranib(Cand5)

AGN211745(Sirna-027)Pazopanib

Class

Aptamer

MonoclonalantibodyfragmentMonoclonalantibodyDecoyreceptorCorticosteroid

siRNAsiRNA

Tyrosinekinaseinhibitor

Moleculartarget

VEGF165isoformAllVEGF-AisoformsAllVEGF-Aisoforms

AllVEGF-AisoformsandPlGFAntiangiogenic;speci ctargets

unknown,possiblyVEGFandothersVEGF-AmRNAVEGF-R1mRNA

InhibitionofVEGFReceptor1,2,and3tyrosinekinases

ManufacturerOSI/EyetechGenentechGenentechaRegeneron

Bristol-MyersSquibbOPKOHealthAllergan

GlaxoSmithKline

PlGF,placentalgrowthfactor;VEGF,vascularendothelialgrowthfactor.a

InvestigationsoftheclinicaluseofbevacizumabinoculardiseasesareindependentofGenentech.

上一页第2页

你可能喜欢

热门文档

相关文档

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email